[Miscellaneous updates including a new discussion of GTC’s role in Follow-On Biologics. Also fixed a bad link in the 7/5/07 update.]
What is GTC’s business all about? #msg-19391437What is the business model? #msg-20969073GTC’s role in Follow-On Biologics #msg-20965937Musings on GTC’s business-model risk #msg-17935613 Venn diagram of business model #msg-11752181 ATryn HD program in EU is proof of concept #msg-19390137 Edited transcript from 1Q07 conference call (5/3/07) #msg-17607391 Edited transcript from 4Q06 conference call (3/5/07) #msg-9243634 Jan 2006 interview with CEO, Geoff Cox #msg-9352093 2002 interview with Tom Newberry (dated, but still informative) #msg-13171505“Production of Recombinant Therapeutic Proteins in the Milk of Transgenic Animals” (recommended for the technical reader)
ATryn hereditary-deficiency program in U.S. #msg-20966468 Plasma-derived AT in U.S. is in short supply #msg-19342893U.S. ATryn timeline #msg-5607789 Efficacy endpoint is clinical DVT #msg-5609005 Design of control arm #msg-11410659 Likelihood of success #msg-6632420 Patient eligibility and exclusions #msg-11511614 Musings on a U.S. partnership #msg-20966607 Risks/supply constraints of plasma-derived drugs #msg-7306242 Which antithrombin will doctors prescribe?
Other potential uses of ATryn #msg-20967328 Reference list of abstracts and write-ups
GTC-LFB program in Factor VIIa (and other therapies) #msg-13731860Who is LFB? #msg-13956439 Who is LFB? (addendum) #msg-13708619Partnership terms #msg-15247168How the collaboration works #msg-16164190Sky-high FVIIa price (rationale for GTC/LFB program); everything you always wanted to know about FVIIa in practice #msg-16645259 NovoSeven reaches blockbuster status #msg-16968837FVIIa sales projections #msg-13763244Patient pool for initial indication #msg-19404190 rFVIIa as a prophylactic treatment #msg-14084250 NovoSeven for acquired hemophilia #msg-13925693 NovoSeven for trauma #msg-14921693 NovoSeven use in the military #msg-20966607 Risks/supply constraints of plasma-derived drugs